The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Even light-intensity activities such as walking can reduce one’s risk for clinical depression. So, what are the most common ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to ...

Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Higher daily step counts were linked to fewer depressive symptoms and a lower risk for depression in a new meta-analysis.

Rebutting the serotonin theory of depression exposed an important gap in our knowledge. But Joanna Moncrieff's new book ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.